A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
A phase 3 trial of Sacituzumab tirumotecan, Bevacizumab in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) is a phase 3 interventional study registered as NCT07318558 by Merck Sharp & Dohme LLC, with 900 participants planned, started 2026-02-16 and due to reach its primary completion in 2033-02-25. Interventions recorded: Sacituzumab tirumotecan, Bevacizumab, Rescue Medications. Conditions listed: Ovarian Neoplasms, Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl
Shares Sacituzumab tirumotecan, Bevacizumab, Merck & Co. (MSD), Ovarian cancer.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD).
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Sacituzumab tirumotecan, Bevacizumab, Merck & Co. (MSD).
- TrialMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
Shares Bevacizumab, Ovarian cancer.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Bevacizumab, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P
Shares Sacituzumab tirumotecan, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD).